IceCure FY 2025 net loss narrows 5% to USD 15.06 million

Reuters03-17

IceCure FY 2025 net loss narrows 5% to USD 15.06 million

IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no revenue from an exclusive distribution agreement in Japan and higher cost of revenues. FY 2025 net loss was USD 15.06 million, and net loss per share was USD 0.24. Cash and cash equivalents including short-term deposits totaled USD 8.9 million at year-end. Management said U.S. adoption of its ProSense cryoablation system is being supported by FDA clearance for low-risk breast cancer, updated American Society of Breast Surgeons guidance recommending cryoablation for selected patients, and an FDA-approved post-marketing study protocol with enrollment expected to start in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603170830PR_NEWS_USPR_____LN10924) on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620422851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620422851","market":"us","top_or_hot":-1,"title":"IceCure FY 2025 net loss narrows 5% to USD 15.06 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure FY 2025 net loss narrows 5% to USD 15.06 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no revenue from an exclusive distribution agreement in Japan and higher cost of revenues. FY 2025 net loss was USD 15.06 million, and net loss per share was USD 0.24. Cash and cash equivalents including short-term deposits totaled USD 8.9 million at year-end. Management said U.S. adoption of its ProSense cryoablation system is being supported by FDA clearance for low-risk breast cancer, updated American Society of Breast Surgeons guidance recommending cryoablation for selected patients, and an FDA-approved post-marketing study protocol with enrollment expected to start in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603170830PR_NEWS_USPR_____LN10924) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure FY 2025 net loss narrows 5% to USD 15.06 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure FY 2025 net loss narrows 5% to USD 15.06 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure FY 2025 net loss narrows 5% to USD 15.06 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no revenue from an exclusive distribution agreement in Japan and higher cost of revenues. FY 2025 net loss was USD 15.06 million, and net loss per share was USD 0.24. Cash and cash equivalents including short-term deposits totaled USD 8.9 million at year-end. Management said U.S. adoption of its ProSense cryoablation system is being supported by FDA clearance for low-risk breast cancer, updated American Society of Breast Surgeons guidance recommending cryoablation for selected patients, and an FDA-approved post-marketing study protocol with enrollment expected to start in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603170830PR_NEWS_USPR_____LN10924) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8MCqSc:1","article_id":"2620422851","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620422851","pubTimestamp":1773750695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no revenue from an exclusive distribution agreement in Japan and higher cost of revenues. FY 2025 net loss was USD 15.06 million, and net loss per share was USD 0.24. Cash and cash equivalents including short-term deposits totaled USD 8.9 million at year-end. Management said U.S. adoption of its ProSense cryoablation system is being supported by FDA clearance for low-risk breast cancer, updated American Society of Breast Surgeons guidance recommending cryoablation for selected patients, and an FDA-approved post-marketing study protocol with enrollment expected to start in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ICCM":"IceCure Medical Ltd."},"translate_title":"IceCure 2025财年净亏损收窄5%至1506万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":0.9},"content_text":"IceCure FY 2025 net loss narrows 5% to USD 15.06 million\n    \n\n        IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no revenue from an exclusive distribution agreement in Japan and higher cost of revenues. FY 2025 net loss was USD 15.06 million, and net loss per share was USD 0.24. Cash and cash equivalents including short-term deposits totaled USD 8.9 million at year-end. Management said U.S. adoption of its ProSense cryoablation system is being supported by FDA clearance for low-risk breast cancer, updated American Society of Breast Surgeons guidance recommending cryoablation for selected patients, and an FDA-approved post-marketing study protocol with enrollment expected to start in the second half of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603170830PR_NEWS_USPR_____LN10924) on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620422851","isCrawlerRequest":true}